Pfizer-Biontech and Moderna recently announced the first interim efficacy analysis of their Covid-19 vaccines. The financial markets cheered the news as an early marker of success. Divya Rajagopal explains what the trial landmark means
First interim vaccine efficacy results
1. Pfizer-Biontech-bOver 90%
2. Moderna- 94.5%
Stastically, there’s not much difference between 90% and 94.5% efficacy since they lie in a range
What is vaccine efficacy?
It’s the degree by which the infection is reduced in a vaccinated group compared with an unvaccinated one
Essentially, it measures disease prevention by the vaccine among trial participants
It’s based on a randomised 1:1 trial of the vaccine and placebo groups Moderna example
HOW GOOD ARE THESE VACCINES?
Efficacy Vs Effectiveness
Is this data enough? This is indeed a positive development, says Gagandeep Kang, leading vaccine expert. However, the next set of data to watch out for will be whether these numbers hold up after 52 days of dosage, the effectiveness on immunocompromised people, the elderly and children.
Source : Economic Times